Today let’s decode one of the most talked about, least formally studied, and genuinely intriguing treatments floating around the PoTS and dysautonomia world right now. Low dose naltrexone (LDN) keeps coming up in patient communities and increasingly in the published literature. So what does the evidence actually say, and why is a drug developed to treat…
Low Dose Naltrexone and PoTS: Is This the Drug the Community Has Been Waiting For?
The evidence is small, the mechanism is plausible, and a proper trial is finally coming. Here is what we know so far.
